To evaluate the impact of HPV vaccine and the persistence of HPV antibody among HPV-vaccinated women living with HIV in Botswana.

To support key laboratory systems strengthening interventions for early disease detection, disease monitoring, and laboratory based disease surveillance for priority diseases of public health importance in Lagos, Nigeria.

To increase vaccine confidence and access among those most affected by mpox.

To maintain, produce, authenticate and distribute arthropod vectors and associated reagents for the Emerging Infections Resources Program.

To help implement the CDC Foundation programs and activities supporting the Targeted Country Assistance portion of the 2022-2025 Partners’ Engagement Framework.

To build community resilience against weather events by supporting local disaster preparedness programs through community-based organizations in the Midwest, with a focus on rural areas.

To support the introduction of a change in Burkina Faso’s infant pneumococcal vaccine schedule to include a booster dose and to evaluate the impact of the country’s capacity to control pneumococcal disease among children and adults.

To provide project management services to include management of design and performance by CDC of an animal research study involving application of microarray patches (MAPs) containing antiretrovirals for HIV treatment to rhesus macaques.

To evaluate the impact of a pneumococcal conjugate vaccine schedule change in Mozambique on vaccine-type pneumococcal carriage and invasive pneumococcal disease; and serotype 1 colonization among patients with suspected pneumonia and serotype 1 disease among children and adults.

To support a literature review of pneumococcal conjugate vaccines (PCV) dosing schedules and impact assessments to guide discussions about potential changes to current guidance on PCV schedules, an analysis needed to support the WHO Strategic Advisory Group of Experts on Immunization PCV Working Group.

To provide laboratory support for the analysis of immunogenicity and shedding of new oral Poliovirus vaccines in human clinical trials and related issues for polio endgame.

To improve use of antibiotics in outpatient settings, where most prescribing occurs, by providing antibiotic stewardship resources for state health departments and state Medicaid agencies.

To evaluate the efficacy of injectable pre-exposure prophylaxis (PrEP) in HIV-uninfected populations.

To ensure impact and effectiveness of rotavirus vaccines and sustain vaccine use by policy makers, physicians and parents to increase the speed of adoption of vaccine by other countries in Africa and around the world.

To develop cell culture and small animal models of Nipah virus replication and pathogenesis in a biosafety level (BSL) 4 lab.